New VFC Vaccine Presentations Available
to Order in ASIIS
Effective as of June 17, 2022, the US Food and Drug Administration (FDA) approved an expanded indication for VAXNEUVANCE™ to include children 6 weeks through 17 years of age.
Beginning December 1st, 2022, a new 15-valent Pneumococcal Conjugate Vaccine will be available for ordering in ASIIS. VAXNEUVANCE™ may be used where PCV13 is recommended.
|
Indications and Usage
VAXNEUVANCE™ is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.
The presentation is available in a prefilled syringe (SYR) 10-pack, NDC: 00006-4329-03
 |
|
Beginning December 1st, 2022, an additional Measles, Mumps, and Rubella (MMR) vaccine will be available for ordering in ASIIS. |
Indications and Usage
PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
The presentation is available in Single Dose Vials (SDV) 10-pack, NDC: 58160-0824-15
Resource Links:
CDC Recommended Child and Adolescent Immunization Schedule for age 18 years or younger, U.S. 2022
CDC Catch-up Immunization Schedule for persons aged 4 months – 18 years who start late or who are more than 1 month behind, U.S. 2022
MMR ACIP Vaccine Recommendations (Measles, Mumps and Rubella)
Pneumococcal ACIP Vaccine Recommendations
GSK - Priorix (Measles, Mumps, and Rubella Live) Package Insert
MERCK - VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Package Insert
The Arizona Immunization Program Office (AIPO) has clinical staff available to assist with your immunization questions (or contact your local county health department).
Kate Whitman, MSE, BSN Kathleen.Whitman@azdhs.gov, 480-259-5342
Sharon Sweeney, MPH, BSN Sharon.Sweeney@azdhs.gov, 480-261-5557
|
